Literature DB >> 17673672

Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats.

Takayuki Ito1, Takashi Okada, Hiroshi Miyashita, Tatsuya Nomoto, Mutsuko Nonaka-Sarukawa, Ryosuke Uchibori, Yoshikazu Maeda, Masashi Urabe, Hiroaki Mizukami, Akihiro Kume, Masafumi Takahashi, Uichi Ikeda, Kazuyuki Shimada, Keiya Ozawa.   

Abstract

Pulmonary arterial hypertension (PAH) is a fatal disease associated with inflammation and pathological remodeling of the pulmonary artery (PA). Interleukin (IL)-10 is a pleiotropic antiinflammatory cytokine with vasculoprotective properties. Here, we report the preventive effects of IL-10 on monocrotaline-induced PAH. Three-week-old Wistar rats were intramuscularly injected with an adeno-associated virus serotype 1 vector expressing IL-10, followed by monocrotaline injection at 7 weeks old. IL-10 transduction significantly improved survival rates of the PAH rats 8 weeks after monocrotaline administration compared with control gene transduction (75% versus 0%, P<0.01). IL-10 also significantly reduced mean PA pressure (22.8+/-1.5 versus 29.7+/-2.8 mm Hg, P<0.05), a weight ratio of right ventricle to left ventricle plus septum (0.35+/-0.04 versus 0.42+/-0.05, P<0.05), and percent medial thickness of the PA (12.9+/-0.3% versus 21.4+/-0.4%, P<0.01) compared with controls. IL-10 significantly reduced macrophage infiltration and vascular cell proliferation in the remodeled PA in vivo. It also significantly decreased the lung levels of transforming growth factor-beta1 and IL-6, which are indicative of PA remodeling. In addition, IL-10 increased the lung level of heme oxygenase-1, which strongly prevents PA remodeling. In vitro analysis revealed that IL-10 significantly inhibited excessive proliferation of cultured human PA smooth muscle cells treated with transforming growth factor-beta1 or the heme oxygenase inhibitor tin protoporphyrin IX. Thus, IL-10 prevented the development of monocrotaline-induced PAH, and these results provide new insights into the molecular mechanisms of human PAH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673672     DOI: 10.1161/CIRCRESAHA.107.153023

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  46 in total

1.  Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Authors:  Eleni Vergadi; Mun Seog Chang; Changjin Lee; Olin D Liang; Xianlan Liu; Angeles Fernandez-Gonzalez; S Alex Mitsialis; Stella Kourembanas
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

2.  Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Lahouaria Hadri; Razmig G Kratlian; Ludovic Benard; Bradley A Maron; Peter Dorfmüller; Dennis Ladage; Christophe Guignabert; Kiyotake Ishikawa; Jaume Aguero; Borja Ibanez; Irene C Turnbull; Erik Kohlbrenner; Lifan Liang; Krisztina Zsebo; Marc Humbert; Jean-Sébastien Hulot; Yoshiaki Kawase; Roger J Hajjar; Jane A Leopold
Journal:  Circulation       Date:  2013-06-26       Impact factor: 29.690

3.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

4.  Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension.

Authors:  Daniela Farkas; A A Roger Thompson; Aneel R Bhagwani; Schuyler Hultman; Hyun Ji; Naveen Kotha; Grant Farr; Nadine D Arnold; Adam Braithwaite; Helen Casbolt; Jennifer E Cole; Ian Sabroe; Claudia Monaco; Carlyne D Cool; Elena A Goncharova; Allan Lawrie; Laszlo Farkas
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

5.  Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage.

Authors:  Yuhong Wang; Zhongjie Sun
Journal:  Hypertension       Date:  2009-07-27       Impact factor: 10.190

6.  The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.

Authors:  Yoh Arita; Yasushi Sakata; Takao Sudo; Tetsuo Maeda; Ken Matsuoka; Keito Tamai; Kaori Higuchi; Wataru Shioyama; Yoshikazu Nakaoka; Yuzuru Kanakura; Keiko Yamauchi-Takihara
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 7.  Heme Oxygenases in Cardiovascular Health and Disease.

Authors:  Anita Ayer; Abolfazl Zarjou; Anupam Agarwal; Roland Stocker
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

8.  Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB.

Authors:  José L Miguel-Carrasco; Sonia Zambrano; Antonio J Blanca; Alfonso Mate; Carmen M Vázquez
Journal:  J Inflamm (Lond)       Date:  2010-05-12       Impact factor: 4.981

Review 9.  Novel approaches to treat experimental pulmonary arterial hypertension: a review.

Authors:  S Umar; P Steendijk; D L Ypey; D E Atsma; E E van der Wall; M J Schalij; A van der Laarse
Journal:  J Biomed Biotechnol       Date:  2010-03-22

10.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.